Search This Blog

Wednesday, September 21, 2022

Sesen Bio and Carisma Therapeutics Announce Merger Agreement

 Transaction to create a well-funded, clinical-stage biotechnology company advancing engineered macrophages for the treatment of cancer and other serious disorders

Combined company expected to have approximately $180 million of cash, cash equivalents and marketable securities at close, including $30 million from a concurrent financing by Carisma, which is expected to fund the combined company through 2024

Cash runway of combined company expected to enable multiple clinical readouts across Carisma programs

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.